Actualising the power of antibody-drug conjugates as cancer therapeutics
Antibody-drug conjugates (ADCs) are designed to be highly-targeted therapies with the potential to maximise the potency of a treatment while reducing unwanted side effects on healthy tissues. Some 20 years after the first ADC product approval, Dominik Schumacher and Jonas Helma-Smets of Tubulis GmbH discuss how improved and optimised technologies…







![Internal structure of a powder inhaler revealed using CT scan [Adapted from Scan of the Month].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Inhaler-feature-300x278.png)
![Internal structure of a powder inhaler revealed using CT scan [Adapted from Scan of the Month].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Inhaler-feature.png)
























